Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Next Previous
Trial Profile

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zilovertamab vedotin (Primary)
  • Indications Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Ewing's sarcoma; Follicular lymphoma; Mantle-cell lymphoma; Neuroblastoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Richter's syndrome; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LIGHTBEAM-U01 Substudy 01 A
  • Sponsors ATAI Life Sciences; Merck Sharp & Dohme Corp.

Most Recent Events

  • 30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 20 Aug 2024 Planned initiation date changed from 13 Aug 2024 to 31 Aug 2024.
  • 05 Aug 2024 Planned initiation date changed from 27 Jun 2024 to 13 Aug 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top